US Food and Drug Administration (US FDA) has imposed an import alert for the drug maker Wockhardt’s Chikalthana facility at Aurangabad. An import alert results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices.
Meanwhile, the company dropped from the Morgan Stanley Capital International (MSCI) India index with effect from November 26, 2013. MSCI is a leading provider of benchmark indices globally.
Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.
